Altasciences Marks Major Development Milestone for Steel Therapeutics’ Fizurex™
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Candidate Fizurex™ Altasciences has announced the successful completion of a pivotal toxicology study for Steel Therapeutics Inc.’s lead investigational therapy, Fizurex™,…
Caidya and Simbec-Orion Announce Strategic Merger
Caidya and Simbec-Orion Unite to Create Global Specialty CRO for End-to-End Drug Development Caidya has announced a strategic combination with Simbec-Orion, marking a significant milestone in the clinical research industry…
BeOne Reports Positive Phase 3 BRUKINSA Results in Frontline MCL
BRUKINSA Phase 3 Trial Shows Chemotherapy-Free Promise for Frontline Mantle Cell Lymphoma BeOne Medicines Ltd. has announced positive topline findings from its pivotal Phase 3 MANGROVE clinical trial, marking a…
Novocure’s Optune Pax® Receives CE Mark for Pancreatic Cancer
Novocure Secures CE Mark for Optune Pax in Locally Advanced Pancreatic Cancer Novocure has achieved a significant regulatory milestone after receiving the CE (Conformité Européenne) Mark for Optune Pax®, authorizing…
Kriya Selected for FDA PreCheck Pilot Program
Kriya Therapeutics Selected for FDA PreCheck Pilot Program to Advance U.S. Gene Therapy Manufacturing Kriya Therapeutics, Inc., a biotechnology company focused on developing durable gene therapies for chronic diseases, has…
Samsung Bioepis Reports Positive Phase 1 and Phase 3 Data for Keytruda Biosimilar SB27
Samsung Bioepis Reports Positive Phase 1 and Phase 3 Results for SB27, Its Proposed Pembrolizumab Biosimilar Samsung Bioepis Co., Ltd. has announced encouraging topline results from its Phase 1 and…
Feinstein Institutes Decode Ancient Reflex to Advance Brain Injury Treatment
Feinstein Institutes Uncover Ancient Reflex Linked to Future Brain Injury Therapies Researchers at Northwell Health’s Feinstein Institutes for Medical Research have uncovered the molecular mechanism behind one of the body’s…
Biocytogen Prevails in Landmark RenNano® Patent Case Against Harbour
Biocytogen Secures Favorable Court Ruling in Patent Dispute, Reinforcing Confidence in Its RenNano® Technology Platform Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SSE: 688796; HKEX: 02315) has announced a significant legal victory…
Tenpoint Therapeutics Launches YUVEZZI™ Consumer Awareness Campaign
Tenpoint Therapeutics Launches National ‘Friends of the Presbyopians’ Campaign to Raise Awareness of YUVEZZI for Age-Related Near Vision Loss Tenpoint Therapeutics, Ltd., a global commercial ophthalmic pharmaceutical company dedicated to…
Genentech’s Enspryng Receives FDA Priority Review for TED
Genentech’s Enspryng Receives FDA Priority Review for Thyroid Eye Disease, Advancing a Potential New Treatment Option Genentech, a member of the Roche Group, has announced that the U.S. Food and…
Genmab Reports Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in R/R DLBCL
Genmab Reports Positive Phase 3 Results for Fixed-Duration Epcoritamab Combination in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Genmab A/S has announced positive topline results from its pivotal Phase 3…
Enhertu Approved in EU as First Tumour-Agnostic HER2-Directed Therapy
Enhertu Gains EU Approval for Previously Treated HER2-Positive Solid Tumours AstraZeneca and Daiichi Sankyo have announced that the European Commission (EC) has approved Enhertu® (trastuzumab deruxtecan) as a monotherapy for…